Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients |
| October 31, 2020 | October 2020 Bond Updates |
|
BRUSSELS, Oct. 31, 2020 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin... |
| View more at: https://www.prnewswire.com:443/news-releases/bimekizumab-phase-3-data-shows-superior-skin-clearance-over-humira-in-moderate-to-severe-psoriasis-patients-301164103.html |
| Related News |
|